| Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript |
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants David Amsellem - Piper Sandler Eason Lee - Leerink Partners Jason Dorr - Oppenheimer Chase Knickerbocker - Craig-Hallum Operator Good morning. Thank you for attending today's Xeris Biopharma First Quarter 2025 Results Conference Call. |
seekingalpha.com |
2025-05-08 18:15:08 |
Czytaj oryginał (ang.) |
| Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates |
Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.14 per share a year ago. |
zacks.com |
2025-05-08 13:20:47 |
Czytaj oryginał (ang.) |
| Xeris Biopharma Reports Record First Quarter 2025 Financial Results |
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. “We're very pleased with our strong start to the year, delivering another quarter of outstanding revenue growth,” said John Shannon, Xe. |
businesswire.com |
2025-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings |
Xeris Biopharma Holdings, Inc. has shown consistent double-digit growth and is expected to continue this trend, with Q1 earnings projected to drive the share price higher. Key metrics to watch include Gvoke and Recorlev revenues, EPS, adjusted EBITDA, and cash flow, as these will determine Xeris's path to profitability. Risks include potential underperformance in product revenue, rising SG&A expenses, and any delays in pipeline programs like XP-8121. |
seekingalpha.com |
2025-05-07 15:51:08 |
Czytaj oryginał (ang.) |
| Xeris Announces Changes to Its Board of Directors |
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy. In addition. |
businesswire.com |
2025-03-28 10:00:00 |
Czytaj oryginał (ang.) |
| Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? |
Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
zacks.com |
2025-03-20 13:15:35 |
Czytaj oryginał (ang.) |
| Xeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call Transcript |
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Oren Livnat - H.C. Wainwright Glen Santangelo - Jefferies David Amsellem - Piper Sandler Leland Gershell - Oppenheimer Mazahir Alimohamed - Leerink Partners Operator Good morning, and welcome to the Xeris Biopharma Fourth Quarter and Full Year 2024 Financial Results. |
seekingalpha.com |
2025-03-06 12:52:55 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings |
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-03-06 12:30:45 |
Czytaj oryginał (ang.) |
| Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates |
Xeris Biopharma (XERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.10 per share a year ago. |
zacks.com |
2025-03-06 11:15:23 |
Czytaj oryginał (ang.) |
| Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release |
Xeris Biopharma (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-26 13:05:26 |
Czytaj oryginał (ang.) |
| Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer |
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and. |
businesswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness |
Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON, Va. , Jan. 21, 2025 /PRNewswire/ -- The American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia (low blood glucose, also called low blood sugar), in line with the ADA's recently updated Standards of Care in Diabetes—2025 (Standards of Care).1 "Severe hypoglycemia is life-threatening, and people with diabetes on blood glucose-lowering medication are at risk for hypoglycemia. |
prnewswire.com |
2025-01-21 11:00:00 |
Czytaj oryginał (ang.) |
| Xeris Expects to Exceed Full-Year 2024 Financial Guidance |
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announced 2024 total revenue guidance of $198 million to $202 million. The Company also anticipates ending 2024 with over $71 million in cash, cash equivalents, and short-term investments, generating positive cash flow in the fourth quarter. “We achieved another record quarter of exceptional total revenue growth with reve. |
businesswire.com |
2025-01-10 09:00:00 |
Czytaj oryginał (ang.) |
| Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on January 2, 2025, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 181,500 shares of its common stock to 19 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Eq. |
businesswire.com |
2025-01-06 18:15:00 |
Czytaj oryginał (ang.) |
| Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference |
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 8:00am Eastern Time. A live webcast of the event will be available on the 'Events &. |
businesswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript |
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants John Shannon - Chief Executive Officer Steve Pieper - Chief Financial Officer Allison Wey - Senior Vice President of Investor Relations, Corporate Communications Conference Call Participants Chase Knickerbocker - Craig-Hallam Leland Gershell - Oppenheimer. Oren Livnat - HC Wainwright Nik Gasic - Leerink Partners David Amsellem - Piper Sandler Operator Hello and welcome to the Xeris Biopharma Third Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-11-08 13:50:27 |
Czytaj oryginał (ang.) |
| Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for Xeris Biopharma (XERS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-11-08 12:30:18 |
Czytaj oryginał (ang.) |
| Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates |
Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.09 per share a year ago. |
zacks.com |
2024-11-08 11:10:20 |
Czytaj oryginał (ang.) |
| Xeris Biopharma Reports Third Quarter 2024 Financial Results |
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2024. “We are proud to report our record-breaking quarter with total revenue of our $54 million led by strong demand of Recorlev® and Gvoke®. Our product revenue growth of 2. |
businesswire.com |
2024-11-08 09:00:00 |
Czytaj oryginał (ang.) |
| Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 |
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2024 financial results before the open of the U.S. financial markets on Friday, November 8, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss t. |
businesswire.com |
2024-10-31 10:00:00 |
Czytaj oryginał (ang.) |
| Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive |
Xeris Biopharma Holdings, Inc. is an overlooked specialty pharmaceutical company with three FDA-approved products, utilizing its proprietary XeriSol and XeriJect technologies to develop innovative injectable drug formulations. Gvoke and Recorlev drive Xeris' rapid growth, with Gvoke holding 34% of the retail glucagon market and Recorlev expanding its patient base by 124%. Xeris' strategic partnerships and promising pipeline, particularly XP-8121 for hypothyroidism, offer strong potential for value creation and long-term growth. |
seekingalpha.com |
2024-10-25 16:50:26 |
Czytaj oryginał (ang.) |
| Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips + |
The 'Undercovered' Dozen highlights 12 lesser-covered stocks from October 4th - 10th, aiming to inspire discussion and provide investment ideas. WW International's pivot to GLP-1 medications raises concerns for Dilantha De Silva about growth and customer churn, leading to a bearish stance despite recent stock gains. Fresenius Medical Care shows Wolf Report potential for growth despite recent earnings declines, with a BBB rating and attractive yield as rate cuts loom. |
seekingalpha.com |
2024-10-11 18:00:29 |
Czytaj oryginał (ang.) |
| Xeris Biopharma: Time For A Reassessment |
Xeris Biopharma is trading above my Buy Threshold of $2.76 and is nearing a potential breakout above the $3.25 resistance level. The company shows strong revenue growth, driven by products like Gvoke and Recorlev, despite not yet reporting a positive EPS. Risks include intense competition and potential need for additional funding, but projected revenue growth suggests significant upside potential. |
seekingalpha.com |
2024-10-09 15:33:26 |
Czytaj oryginał (ang.) |
| Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2024, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 364,000 shares of its common stock to 42 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Eq. |
businesswire.com |
2024-10-04 20:05:00 |
Czytaj oryginał (ang.) |
| 3 Penny Stocks to Buy With $500 |
Are you interested in investing in penny stocks? |
247wallst.com |
2024-08-30 14:20:24 |
Czytaj oryginał (ang.) |
| Xeris Biopharma Holdings, Inc. (XERS) Q2 2024 Earnings Call Transcript |
Start Time: 08:30 January 1, 0000 9:03 AM ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants John Shannon - CEO Steven Pieper - CFO Allison Wey - SVP, IR and Corporate Communications Conference Call Participants Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Rohan Mathur - Oppenheimer Operator Hello, everyone, and welcome to today's Xeris Biopharma Second Quarter 2024 Financial Results Call. My name is Drew, and I'll be your operator today. |
seekingalpha.com |
2024-08-08 15:56:10 |
Czytaj oryginał (ang.) |
| Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates |
Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.14 per share a year ago. |
zacks.com |
2024-08-08 13:25:59 |
Czytaj oryginał (ang.) |
| Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know |
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-08-01 15:05:35 |
Czytaj oryginał (ang.) |
| Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy? |
From a technical perspective, Xeris Biopharma Holdings, Inc. (XERS) is looking like an interesting pick, as it just reached a key level of support. XERS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world. |
zacks.com |
2024-07-24 14:56:08 |
Czytaj oryginał (ang.) |
| Xeris Biopharma unveils CEO succession plan, John Shannon to lead company |
Xeris Biopharma Holdings (NASDAQ:XERS) announced a CEO succession plan with John Shannon taking over from Paul Edick on August 1, 2024. Edick, the current CEO and chairman, will retire from his roles after more than seven years with the company. |
proactiveinvestors.com |
2024-07-08 13:55:28 |
Czytaj oryginał (ang.) |
| Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 196,000 shares of its common stock to 26 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Equit. |
businesswire.com |
2024-07-03 17:05:00 |
Czytaj oryginał (ang.) |
| Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024 |
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced it presented a post-hoc analysis from its previously published SONICS study on the effects of levoketoconazole (Recorlev®) in adults with Cushing's syndrome at ENDO 2024 in Boston, June 1-4, 2024. “The results of this analysis suggest that pati. |
businesswire.com |
2024-06-03 11:00:00 |
Czytaj oryginał (ang.) |
| Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) |
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company's XeriSol™ formulation technology to enable a novel once-weekly SC injec. |
businesswire.com |
2024-05-30 11:30:00 |
Czytaj oryginał (ang.) |
| Xeris to Participate in the Jefferies Global Healthcare Conference |
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6 at 2:00pm Eastern Time. A live webcast of the event will be available on the 'Events & Presentations. |
businesswire.com |
2024-05-30 11:00:00 |
Czytaj oryginał (ang.) |